HEALTH

Life Support storming retail with new recovery, energy shots
Matrixx Initiatives releases latest Zicam cold buster
BRIDGEWATER, N.J. -- Matrixx Initiatives announced Monday the launch of Zicam Cold Remedy Ultra Berry Lemonade Crystals, the latest addition to Zicam's cold shortening line-up.

The new product combines the power of zinc, which reduces the duration of the common cold, and elderberry, a popular immunity boosting ingredient.

Boehringer Ingelheim, Lilly launch campaign on Type 2 diabetes, heart disease link

RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly & Co. have launched an educational campaign to help raise awareness of the link between heart disease and Type 2 diabetes. The “For Your SweeHeart: Where diabetes and heart disease meet” campaign launch follows a survey by the two companies that found three-in-four Americans and two-in-three people with Type 2 diabetes don’t know that heart disease is the No. 1 health-related killer of Type 2 diabetes patients.
New Knowhen Advanced Ovulation Test IDs patient’s 5 most fertile days

NEWARK, N.J. — The new saliva-based Knowhen Advanced Ovulation Test is looking to help patients predict the likelihood of becoming pregnant on a given day. The test is a daily monitoring method that features a reusable mini-ovulation microscope to monitor the gradual increase of estrogen in saliva to identify the five most fertile days in the ovulation cycle.
FDA approves Novo Nordisk’s Xultophy 100/3.6 for Type 2 diabetes

SILVER SPRING, Md. — Novo Nordisk announced Monday that the Food and Drug Administration had approved its Xultophy 100/3.6 (insulin degludec 100 units/ML and liraglutide 3.6 mg/mL). The drug is indicated to improve glycemic control in adults with Type 2 diabetes inadequately controlled on less than 50 units of basal insulin daily or less than or equal to 1.8 mg of liraglutide daily.
Sanofi’s Soliqua 100/33 for Type 2 diabetes gets FDA nod

SILVER SPRING, Md. — The Food and Drug Administration has approved Sanofi’s Soliqua 100/33 (insulin glargine 100 units/mL and lixisenatide 33mcg/mL), the company announced Monday. The drug is indicated to treat adults with Type 2 diabetes that’s inadequately controlled on basal insulin or lixisenatide.
FDA approves Ascensia’s app-enabled blood glucose monitoring system

PARSIPPANY, N.J. — Ascensia Diabetes Care announced Monday that the Food and Drug Administration had approved the company’s Contour Next One blood glucose monitoring system. The blood glucose smart meter can connect to mobile devices via Bluetooth to facilitate easier management within the Contour Diabetes app.
SimpleMD taps into Mediterranean Diet with new meal replacement entry

AVENTURA, Fla. -- SimpleMD recently launched a line of protein bars inspired by the Mediterranean Diet. According to the company, they are they only protein bars made with extra virgin olive oil and red wine.

The "hero" of the Mediterranean Diet is olive oil; and the Diet itself has been linked to improved cardiovascular health, reduction in cancer and Alzheimer's risk and improvements in arthritis and age-related macular degeneration.
APhA celebrates 20 years of immunizing pharmacists
Female Health Company planning launch of PE remedy Preboost

MIAMI -- The Female Health Company on Thursday announced plans to launch its Preboost premature ejaculation wipes into the U.S. market by the end of the year, following positive clinical trials.